These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10426663)

  • 1. PALA versus streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma.
    Witte RS; Ryan LM; Schutt AJ; Carbone PP; Engstrom PF
    Invest New Drugs; 1998-1999; 16(4):315-8. PubMed ID: 10426663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
    Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
    Rosvold E; Schilder R; Walczak J; DiFino SM; Flynn PJ; Banerjee TK; Heim WJ; Engstrom PF; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1992; 29(4):305-8. PubMed ID: 1537077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
    Buroker TR; Moertel CG; Fleming TR; Everson LK; Cullinan SA; Krook JE; Mailliard JA; Marschke RF; Klaassen DJ; Laurie JA
    J Clin Oncol; 1985 Dec; 3(12):1624-31. PubMed ID: 2933492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
    Köhne CH; Harstrick A; Hiddemann W; Schöffski P; Wilke H; Bokemeyer C; Dörken B; Schmoll HJ
    Eur J Cancer; 1997 Oct; 33(11):1896-9. PubMed ID: 9470854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
    Harstrick A; Köhne CH; Hiddemann W; Preusser P; Strumberg D; Berns T; Seeber S; Wilke H; Schmoll HJ
    Ann Oncol; 1997 Sep; 8(9):917-8. PubMed ID: 9358946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of PALA on the pharmacokinetics of 5-fluorouracil.
    Nassim MA; Rouini MR; Cripps MC; Shirazi FH; Veerasinghan S; Molepo JM; Obrocea M; Redmond D; Bates S; Fry D; Stewart DJ; Goel R
    Oncol Rep; 1998; 5(1):217-21. PubMed ID: 9458325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer.
    Mann GB; Hortobagyi GN; Buzdar AU; Yap HY; Valdivieso M
    Cancer; 1985 Sep; 56(6):1320-4. PubMed ID: 4027872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
    Whitehead RP; Benedetti JK; Abbruzzese JL; Ardalan B; Goodwin JW; Balcerzak SP; Samlowski WE; Lenz HJ; Macdonald JS
    Invest New Drugs; 2004 Aug; 22(3):335-41. PubMed ID: 15122082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
    Jodrell DI; Oster W; Kerr DJ; Canney PA; Yosef H; Steward WP; Kaye SB; Cassidy J
    Eur J Cancer; 1994; 30A(7):950-5. PubMed ID: 7946590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma.
    Casper ES; Baselga J; Smart TB; Magill GB; Markman M; Ranhosky A
    Cancer Chemother Pharmacol; 1991; 28(1):51-4. PubMed ID: 2040033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group.
    Kleeberg UR; Mulder JH; Rümke P; Thomas D; Rozencweig M
    Eur J Cancer Clin Oncol; 1982 Aug; 18(8):723-6. PubMed ID: 6217975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of PALA (NSC 224131) in patients with advanced ovarian carcinoma. A Gynecologic Oncology Group study.
    Muss HB; Slavik M; Bundy B; Stehman FB; Creasman WT
    Am J Clin Oncol; 1984 Jun; 7(3):257-60. PubMed ID: 6731346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PALA, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma. A pilot study.
    Voigt H; Kleeberg UR
    Cancer; 1984 May; 53(10):2058-62. PubMed ID: 6231091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
    Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
    Langer CJ; Schaebler D; Sauter E; DeMaria D; Johnson C; Reilly DM; Clark J; Leighton J; Aks C; Litwin S; Ridge JA
    Head Neck; 1998 Aug; 20(5):385-91. PubMed ID: 9663665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II evaluation of PALA in patients with refractory metastatic sarcomas.
    Kurzrock R; Yap BS; Plager C; Papdopoulos N; Benjamin RS; Valdivieso M; Bodey GP
    Am J Clin Oncol; 1984 Aug; 7(4):305-7. PubMed ID: 6741860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
    J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
    Kemeny N; Conti JA; Seiter K; Niedzwiecki D; Botet J; Martin D; Costa P; Wiseberg J; McCulloch W
    J Clin Oncol; 1992 May; 10(5):747-52. PubMed ID: 1569447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group.
    Bramwell V; Van Oosterom A; Mouridsen HT; Cheix F; Somers R; Thomas D; Rozencweig M
    Eur J Cancer Clin Oncol; 1982 Jan; 18(1):81-4. PubMed ID: 6211362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.